SCIGEN PTE. LTD.

SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration. SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.

SciGen is a global biopharmaceutical company focused on developing, marketing, and commercializing innovative and affordable healthcare products. We leverage our commercialization and networking capabilities to in-license and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases. With operations in Asia, Australia, China, the Philippines, and present commercially in all 6 continents, we strive to deliver hope and make a real and lasting difference to patients and their families.